Latest Advances in Lung Cancer Research

A new study offers hope for people with EGFR lung cancer whose treatment stopped working. Published in the New England Journal of Medicine, it found that osimertinib and savolitinib together beat chemotherapy.

Tarlatamab small cell lung cancer research just took a major step forward. A new study in the New England Journal of Medicine found that adding tarlatamab to standard maintenance treatment helped patients live much longer.

Cancer researchers are increasingly studying the whole body, not just the tumor, and listening more closely to patients’ own experiences.

A new targeted therapy produced a 94% response rate in ROS1-positive lung cancer, with strong results even against brain metastases.

The CDC’s 2026 report finds falling lung cancer death rates are the biggest reason U.S. cancer mortality keeps declining after more than 20 years.

A new study found blood changes linked to air pollution exposure show up years before a lung cancer diagnosis.

Not long ago, lung cancer had almost no organized patient advocacy and nowhere near the visibility that breast cancer or pediatric cancer communities had built. A new article in the Journal of Thoracic Oncology, co-written by four advocates and researchers — including LCFA’s own Jill Feldman — traces how that changed over the past two decades, and what’s still unfinished.

Patients with ROS1 lung cancer have a new option. On July 22, 2026, the FDA approved zidesamtinib, sold as Jideytro. The maker is Nuvalent, Inc.

Discover why 9 in 10 lung cancer patients miss out on clinical trial discussions and how asking one key question early can unlock life-saving options.